Deals
While Boehringer Ingelheim hasn’t yet revealed what diseases it will go after, Sitryx’s oral drug candidate could potentially be disease-modifying for a variety of autoimmune and inflammatory conditions.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The agreement would have created a spin-off gene therapy company and merged it with ARYA IV to create a new, publicly-traded entity called Caritas Therapies.
Intellia announced a lease agreement to develop a 140,000 square-foot manufacturing facility in Waltham, MA, while Moderna and Thermo Fisher Scientific sign a long-term deal.
GlaxoSmithKline unveiled plans for its new spinout in the consumer health division, Haleon. It is expected to be in place by mid-2022.
HOOKIPA Pharma Inc.’s shares have soared after stating it amended and restated a collaboration and license agreement with Gilead Sciences to develop immunotherapies against HIV.
Shares of ImmunoGen are climbing this morning after the company announced an antibody drug conjugate (ADCs) collaboration with Eli Lilly valued at up to $1.7 billion.
Stoughton, Mass.-based Collegium Pharmaceutical is expanding its pain-treating portfolio with a $604 million buyout of Raleigh’s BioDelivery Sciences International (BDSI).
New York-based Ovid Therapeutics and Healx have entered a strategic partnership to investigate the compound gaboxadol to treat Fragile X Syndrome (FXS).
On Thursday, Intellia announced it had paid Rewrite shareholders $45 million upfront. Additionally, the transaction involved a transfer of $155 million in the form of Intellia common stock and cash.
The portfolio of STING inhibitors is designed to treat autoimmune and inflammatory diseases.
Various pharmaceutical companies announced collaborations and licensing agreements from January 31 to February 1.